 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| LAVA-1207 / LAVA Therap
Enrollment change, Trial completion date, Trial primary completion date, Metastases: KEYNOTE F73: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer (clinicaltrials.gov) - May 16, 2024
P1/2, N=180, Recruiting, Sponsor: Lava Therapeutics
N=66 --> 180 | Trial completion date: Mar 2024 --> Apr 2027 | Trial primary completion date: Sep 2023 --> Apr 2027
- Keytruda (pembrolizumab) / Merck (MSD), LAVA-1207 / LAVA Therap
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC). (Hall A; Poster Bd #: 149b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3072;
P1/2
Dose escalation is ongoing. Expansion arm(s) will be included based on available data from part 1 of the study and may include one or more of LAVA-1207, LAVA-1207 with low dose IL-2, or LAVA-1207 in combination with pembrolizumab.
- ||| LAVA-1207 / LAVA Therap
P1/2 data: Conferences #GU23 - 16-18 Feb $LVTX is presenting LAVA-1207 phase 1/2 data in mCRPC Roadshows Analyst roadshow: New York, Boston, San Francisco - 13-17 Feb (3/3) (Twitter) - Feb 12, 2023
- LAVA-1207 / LAVA Therap
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). (On Demand | Level 1, West Hall; Poster Board No. E13) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_280;
P1/2
Expansion arm(s) will be included based on available data from part 1 of the study and may include one or more of LAVA-1207, LAVA-1207 with low dose IL-2, or LAVA-1207 in combination with pembrolizumab. LAVA-1207 has been well tolerated early in dose escalation; further clinical activity including PSA results, response assessment, and pharmacodynamic data will clarify determination of an optimal biological active dose.
- |||| LAVA-1207 / LAVA Therap
New P1/2 trial, Metastases: KEYNOTE F73: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer (clinicaltrials.gov) - May 11, 2022
P1/2, N=66, Recruiting, Sponsor: Lava Therapeutics
- ||||| LAVA-1207 / LAVA Therap
Clinical: We’re excited to announce treatment of the first patient in our P1/2a #clinicaltrial of LAVA-1207 for #mCRPC. To learn more visit: https://t.co/68ByNkjZGJ @erasmusmcintl @ErasmusOncology @ErasmusMC @MartijnLolkema #prostatecancer #Gammabody #immunooncology #clinicaltrial $LVTX (Twitter) - Feb 1, 2022
- |||| LAVA-1207 / LAVA Therap
New P1/2 trial, Metastases: LAVA-1207 Open Label study in patients with therapy refractory metastatic castration resistant prostate cancer (EUDRACT) - Jul 27, 2021
P1/2, N=66, Ongoing, Sponsor: LAVA Therapeutics N.V.